News Release

Invited presentation for the “AI Biotech & Healthcare” session at BIO Asia-Taiwan 2019 International Conference

At BIO Asia-Taiwan 2019 International Conference (Taipei, July 24-26, 2019), Dr. Shun Doi, President and CEO of CYTLIMIC Inc., gave an invited presentation on CYT001 as a unique application of AI to cancer vaccine development.
Title: Innovative Cancer Vaccine – The Fruit of Integration of AI and Immunology
Session 2 – AI for Biotechnology and Healthcare
The development of Machine Learning-based MHC binding peptide prediction system started in 1998 as a collaboration of computer scientists in NEC and immunologist Prof. Keiko Udaka (Kyoto University, currently Professor of Kochi University). This technology was used in the discovery of Multi-HLA reactive peptides in a collaboration between NEC and Yamaguchi University in 2012. In parallel, a discovery of new combination adjuvant also started in the same collaboration, and the combination of Poly ICLC (TLR3 and MDA5 agonist) and LAG-3Ig (MHC Class II agonist) was discovered as a novel combination immune activator. CYTLIMIC’s peptide vaccine CYT001 is composed of two Multi-HLA reactive peptides (one for HSP70 antigen and the other is for GPC3 antigen), and the combination adjuvant of Poly ICLC (Hiltonol, Oncovir, Inc.) and LAG-3Ig (Eftilagimod Alpha, Immutep Ltd.), a real fruit of the integration of Artificial Intelligence and Immunology.
The topics of the first part is the outline, background of the development of Machine Learning-based MHC binding peptide prediction system. The second topics is the development of CYTLIMIC’s vaccine CYT001 conducted under the collaboration between NEC and Yamaguchi University. The third topics is about clinical studies, and future development of the vaccine.
Anti-PD-(L)1 antibody has shown notable clinical effects in some of advanced cancer patients, but its overall efficacy is still limited. Average response rate is around 20%, except for some specific cancer types, e.g., Hodgkin’s lymphoma, and various combinations are being tested. Among non-responders to anti-PD-(L)1 drug are the patients having “Cold tumor”, where cytotoxic T cells are not reached tumor sites. From the nature of cancer vaccine in activating cytotoxic T cells, it is believed that the combination of anti-PD-(L)1 drug and vaccine will respond in certain portion of remaining 80% non-responders to anti-PD-(L)1 drug. Recent progresses on such combination will also be discussed.
The abstract is also available at the following conference site: